Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million. Under the new deal, Samsung Biologics will offer large-scale commercial manufacturing for drug substance in its Plant 3. In addition, it will support AstraZeneca’s biologics therapeutics.
“This long-term partnership with Samsung Biologics strengthens our manufacturing capabilities, and ensures we are well-positioned to continue to deliver our exciting portfolio of new and established biologics medicines to patients with quality, speed and efficiency,” said Pam Cheng, EVP Global Operations and IT, AstraZeneca.
